MA31143B1 - Proteines de fusion recepteur du fgf/fc solubles modifiees presentant une activite biologique amelioree - Google Patents

Proteines de fusion recepteur du fgf/fc solubles modifiees presentant une activite biologique amelioree

Info

Publication number
MA31143B1
MA31143B1 MA32042A MA32042A MA31143B1 MA 31143 B1 MA31143 B1 MA 31143B1 MA 32042 A MA32042 A MA 32042A MA 32042 A MA32042 A MA 32042A MA 31143 B1 MA31143 B1 MA 31143B1
Authority
MA
Morocco
Prior art keywords
biological activity
modified soluble
improved biological
fusion proteins
soluble fgf
Prior art date
Application number
MA32042A
Other languages
English (en)
Inventor
Sylvie Sordello
Celine Nicolazzi
Mark Nesbit
Beatrice Cameron
Francis Blanche
Marc Trombe
Original Assignee
Centelion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39431092&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31143(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centelion filed Critical Centelion
Publication of MA31143B1 publication Critical patent/MA31143B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur des fusions de Fc de récepteur de FGF soluble modifié, comprenant une fusion d'un fragment ou domaine soluble de la partie de récepteur de FGF (fraction de ciblage ou de liaison) avec une région Fc d'une partie immunoglobuline (fraction de fonction effectrice), ayant une activité biologique améliorée comprenant les activités ADCC/CDC, sur des compositions les contenant et sur un procédé de fabrication de telles molécules de fusion de Fc de récepteur de FGF soluble modifié.
MA32042A 2006-11-28 2009-06-24 Proteines de fusion recepteur du fgf/fc solubles modifiees presentant une activite biologique amelioree MA31143B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06291824 2006-11-28
EP07290042 2007-01-11

Publications (1)

Publication Number Publication Date
MA31143B1 true MA31143B1 (fr) 2010-02-01

Family

ID=39431092

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32042A MA31143B1 (fr) 2006-11-28 2009-06-24 Proteines de fusion recepteur du fgf/fc solubles modifiees presentant une activite biologique amelioree

Country Status (33)

Country Link
US (3) US8119770B2 (fr)
EP (1) EP2092069B2 (fr)
JP (1) JP2010510801A (fr)
KR (1) KR20090102769A (fr)
AR (1) AR063975A1 (fr)
AT (1) ATE509106T1 (fr)
AU (1) AU2007326985C1 (fr)
BR (1) BRPI0719290A2 (fr)
CA (1) CA2668932A1 (fr)
CL (1) CL2007003411A1 (fr)
CO (1) CO6190564A2 (fr)
CR (1) CR10777A (fr)
CY (1) CY1112435T1 (fr)
DK (1) DK2092069T3 (fr)
EA (1) EA018700B1 (fr)
EC (1) ECSP099361A (fr)
GT (1) GT200900137A (fr)
HR (1) HRP20110503T1 (fr)
IL (1) IL198480A0 (fr)
MA (1) MA31143B1 (fr)
MX (1) MX2009005692A (fr)
MY (1) MY145914A (fr)
NI (1) NI200900097A (fr)
NO (1) NO20092414L (fr)
PE (1) PE20081250A1 (fr)
PL (1) PL2092069T3 (fr)
PT (1) PT2092069E (fr)
RS (1) RS51911B (fr)
SI (1) SI2092069T1 (fr)
SV (1) SV2009003272A (fr)
TN (1) TN2009000184A1 (fr)
TW (1) TW200839012A (fr)
WO (1) WO2008065543A2 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2536918A1 (fr) 2003-08-26 2005-03-03 Leland Shapiro Compositions et procedes pour molecules de fusion fc de l'alpha-1 antitrypsine
EP2083081A1 (fr) 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions et procédés pour traiter une maladie avec des protéines de fusion FGFR
CA2732449A1 (fr) 2008-08-04 2010-02-11 Five Prime Therapeutics, Inc. Muteines de region acide de domaine extracellulaire de fgfr
EP2478003A4 (fr) 2009-09-15 2013-05-29 Five Prime Therapeutics Inc Méthodes de croissance des cheveux utilisant les domaines extracellulaires de fgfr4
PL2498799T3 (pl) 2009-11-13 2017-03-31 Five Prime Therapeutics, Inc. Zastosowanie białek domeny zewnątrzkomórkowej FGFR1 do leczenia nowotworów charakteryzujących się mutacjami aktywującymi zależnymi od ligandów w FGFR2
US8685931B2 (en) 2009-12-17 2014-04-01 Five Prime Therapeutics, Inc. Hair growth methods using FGFR3 extracellular domains
FR2958936A1 (fr) 2010-04-14 2011-10-21 Sanofi Aventis Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs
AU2015258172B2 (en) * 2010-11-15 2017-01-12 Five Prime Therapeutics, Inc. Fgfr1 extracellular domain combination therapies
EA025828B1 (ru) * 2010-11-15 2017-02-28 Файв Прайм Терапьютикс, Инк. Комбинированная терапия внеклеточным доменом fgfr1
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) * 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
KR20130132880A (ko) 2010-12-23 2013-12-05 사노피 간암의 치료에 사용하기 위한 ｒｏｂｏ１－ｆｃ 융합 단백질
AR085302A1 (es) 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
CN102219860B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
CN102219859B (zh) 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 拮抗血管新生诱导因子的融合蛋白及其用途
KR102103476B1 (ko) * 2011-06-24 2020-04-23 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
CN107823630A (zh) * 2011-11-14 2018-03-23 戊瑞治疗有限公司 治疗癌症的方法
EP2802653A4 (fr) 2012-01-10 2015-09-02 Univ Colorado Regents Compositions de molécules de fusion de l'alpha-1 antitrypsine, procédés et utilisations associés
KR20160002681A (ko) 2013-01-16 2016-01-08 인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르) 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드
EP2964260A2 (fr) 2013-03-06 2016-01-13 F. Hoffmann-La Roche AG Méthodes de traitement et de prévention de la résistance à un médicament d'un cancer
CA2902530C (fr) * 2013-03-11 2023-05-09 Genzyme Corporation Conjugaison anticorps-medicament specifique d'un site par glyco-ingenierie
US9957313B2 (en) 2013-03-15 2018-05-01 Remegen, Ltd. FGFR-FC fusion proteins and the use thereof
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
WO2014190147A2 (fr) * 2013-05-23 2014-11-27 Five Prime Therapeutics, Inc. Méthodes de traitement du cancer
LT3708583T (lt) 2013-08-01 2022-04-11 Five Prime Therapeutics, Inc. Afukozilinti anti-fgfr2iiib antikūnai
EP4015535A1 (fr) 2014-03-19 2022-06-22 Genzyme Corporation Modification de la glyco-ingéniérie de fractions de ciblage spécifique à un site
US20230190750A1 (en) 2014-06-13 2023-06-22 Genentech, Inc. Methods of treating and preventing cancer drug resistance
TWI791422B (zh) * 2015-11-23 2023-02-11 美商戊瑞治療有限公司 用於癌症治療之單獨fgfr2抑制劑或與免疫刺激劑組合
SG10202112636SA (en) 2017-05-16 2021-12-30 Five Prime Therapeutics Inc Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
JP6967578B2 (ja) * 2017-11-30 2021-11-17 グリフォルス ダイアグノステック ソリューションズ インコーポレーテッド 免疫チェックポイント阻害剤ｐｄ−１及びｐｄ−ｌ１に対する抗体治療をモニタリングするためのイムノアッセイ及び操作されたタンパク質
PE20212075A1 (es) * 2018-01-26 2021-10-26 Genentech Inc PROTEINAS DE FUSION Fc IL-22 Y METODOS DE USO

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288856A (en) 1986-11-20 1994-02-22 Pierre Amiguet Method of isolating acid-stable, biologically active proteins
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5750375A (en) * 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5288855A (en) * 1989-01-23 1994-02-22 Farmitalia Carlo Erba Extracellular form of the human fibroblast growth factor receptor
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5153310A (en) * 1989-02-28 1992-10-06 Du Pont Merck Pharmaceutical Company Il-2 analogs containing n-linked glycosylation sites
DE69033109T2 (de) 1989-07-06 1999-11-18 The Regents Of The University Of California, Oakland Rezeptoren für fibroblasten-wachstumsfaktoren
WO1991017183A1 (fr) * 1990-04-27 1991-11-14 Takeda Chemical Industries, Ltd. Proteines presentant une activite de recepteur de facteur de croissance de fibroblaste
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
AU662107B2 (en) 1990-07-06 1995-08-24 Aventis Pharmaceuticals Inc. Fibroblast growth factor receptors
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US20020045207A1 (en) * 1997-10-31 2002-04-18 Lynne A. Krummen Glycoprotein production process
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US6656728B1 (en) * 1999-02-08 2003-12-02 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
US6612152B2 (en) * 1999-05-01 2003-09-02 James E. Keaton Lifting, servicing, and diagnosing automobiles
US6656738B1 (en) * 1999-11-17 2003-12-02 Bae Systems Integrated Defense Solutions Inc. Internal heater for preconcentrator
EP1299535A2 (fr) * 2000-06-30 2003-04-09 Maxygen Aps Polypeptides glycosyles a extension peptidique
JP4290423B2 (ja) 2000-10-06 2009-07-08 協和発酵キリン株式会社 抗体組成物を生産する細胞
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040110226A1 (en) * 2002-03-01 2004-06-10 Xencor Antibody optimization
EP1498491A4 (fr) * 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc gamma iiia
WO2003085118A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Procede de production de composition anticorps
EP3150630A1 (fr) * 2002-09-27 2017-04-05 Xencor Inc. Variantes fc optimisées et leurs procédés de génération
CA2525969A1 (fr) 2003-05-16 2005-02-24 Receptor Biologix, Inc. Proteines hybrides a intron et procede d'identification et d'utilisation de celles-ci
WO2005035741A1 (fr) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Cellule a genome modifie
DE102004022895A1 (de) 2004-05-10 2005-12-08 Adam Opel Ag Schallabsorbierendes Verkleidungselement
CN103172731A (zh) 2004-07-15 2013-06-26 赞科股份有限公司 优化的Fc变体
US20060223147A1 (en) 2004-08-05 2006-10-05 Kyowa Hakko Kogyo Co., Ltd., Process for producing glycoprotein composition
WO2006047350A2 (fr) 2004-10-21 2006-05-04 Xencor, Inc. Variants d'immunoglobuline igg a fonction effectrice optimisee
AU2006230413B8 (en) 2005-03-31 2011-01-20 Xencor, Inc Fc variants with optimized properties
US20060234347A1 (en) 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
EP1746161A1 (fr) * 2005-07-20 2007-01-24 Cytheris IL-7 glycosylée, préparation et utilisations
EP2083081A1 (fr) * 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions et procédés pour traiter une maladie avec des protéines de fusion FGFR
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES

Also Published As

Publication number Publication date
WO2008065543A3 (fr) 2008-08-14
ECSP099361A (es) 2009-06-30
CR10777A (es) 2009-07-23
AU2007326985B2 (en) 2013-08-15
MY145914A (en) 2012-05-15
TW200839012A (en) 2008-10-01
CA2668932A1 (fr) 2008-06-05
GT200900137A (es) 2011-09-02
EP2092069A2 (fr) 2009-08-26
AR063975A1 (es) 2009-03-04
EP2092069B1 (fr) 2011-05-11
WO2008065543A2 (fr) 2008-06-05
TN2009000184A1 (en) 2010-10-18
US20140030265A1 (en) 2014-01-30
NI200900097A (es) 2010-01-26
EA018700B1 (ru) 2013-10-30
CO6190564A2 (es) 2010-08-19
ATE509106T1 (de) 2011-05-15
JP2010510801A (ja) 2010-04-08
RS51911B (en) 2012-02-29
US8481487B2 (en) 2013-07-09
PT2092069E (pt) 2011-07-29
SV2009003272A (es) 2010-02-05
AU2007326985C1 (en) 2014-02-20
US8119770B2 (en) 2012-02-21
NO20092414L (no) 2009-08-21
KR20090102769A (ko) 2009-09-30
PE20081250A1 (es) 2008-10-07
CL2007003411A1 (es) 2008-07-04
AU2007326985A1 (en) 2008-06-05
HRP20110503T1 (hr) 2011-08-31
DK2092069T3 (da) 2011-08-29
IL198480A0 (en) 2011-08-01
BRPI0719290A2 (pt) 2014-02-25
PL2092069T3 (pl) 2011-10-31
CY1112435T1 (el) 2015-12-09
US20100061979A1 (en) 2010-03-11
MX2009005692A (es) 2009-10-12
US20120195851A1 (en) 2012-08-02
EP2092069B2 (fr) 2013-12-18
SI2092069T1 (sl) 2011-09-30
EA200970515A1 (ru) 2009-12-30

Similar Documents

Publication Publication Date Title
MA31143B1 (fr) Proteines de fusion recepteur du fgf/fc solubles modifiees presentant une activite biologique amelioree
JP6734227B2 (ja) 抗ｃｄ２７６抗体（ｂ７ｈ３）
US11845793B2 (en) Anti-ROR1 antibodies
JP2023153895A (ja) 活性化抗体の特性を定性的および／または定量的に分析する方法およびその使用
EP1189931B1 (fr) Composes de peptide se liant a her2
WO2004019878A3 (fr) Adzymes et leurs utilisations
CN104105711B (zh) 单链抗体及其他异多聚体
ATE466886T1 (de) Adzyme und deren verwendungen
KR101882366B1 (ko) 온코스타틴 m 수용체 항원 결합 단백질
PL374587A1 (en) Pharmaceutical compositions directed to erb-b1 receptors
KR20070073886A (ko) 독성이 감소된 치료제
TNSN07394A1 (en) Antibodies to myostatin
CN115819588A (zh) 新型抗cd19抗体
US20230265206A1 (en) Antibodies against cdcp1 for the treatment and detection of cancer
Jureczek et al. An oligo-His-tag of a targeting module does not influence its biodistribution and the retargeting capabilities of UniCAR T cells
JP2019527033A (ja) 抗第ＩＸ因子Ｐａｄｕａ抗体
Akbari et al. Construction, expression, and activity of a novel immunotoxin comprising a humanized antiepidermal growth factor receptor scFv and modified Pseudomonas aeruginosa exotoxin A
CN108290950A (zh) 抗cd95l抗体
WO2008060814A3 (fr) ANTICORPS DIRIGÉS CONTRE IL-13Rα1 ET LEURS UTILISATIONS
UY30749A1 (es) Fusiones fc con receptor para fgf soluble modificadas, con actividad biologica mejorada
CN114144429B (zh) 针对pd-1和lag-3的双特异性抗体
CN117715942A (zh) 使用抗体-寡核苷酸缀合物的增强的靶向
Albone et al. Generation of therapeutic immunoconjugates via Residue-Specific Conjugation Technology (RESPECT) utilizing a native cysteine in the light chain framework of Oryctolagus cuniculus
CN117279664A (zh) Folr1结合剂、其偶联物及其使用方法
TW202233680A (zh) 具有增加的選擇性之多靶向性雙特異性抗原結合分子